Drug Trial Radar · NCT04543383
A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Jul 27, 2020
Primary completion
Jun 7, 2023
Study completion Jun 9, 2023
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 54 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the reversal of the anticoagulant effects of milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa (rFVIIa) in healthy participants as measured by changes from baselines of the coagulation testing parameters (activated partial thromboplastin time \[aPTT\] and thrombin generation assay \[TGA\]).
Conditions
- Healthy
Interventions
MilvexianDrug
Milvexian will be administered orally.
4-Factor Prothrombin Complex Concentrate (4F-PCC)Biological
4F-PCC will be administered intravenously.
Recombinant Human Factor VIIa (rFVIIa)Biological
rFVIIa will be administered intravenously.
Placebo matching to 4F-PCCBiological
Placebo matching to 4F-PCC will be administered intravenously.
Placebo matching to rFVIIaBiological
Placebo matching to rFVIIa will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Change from Baseline in Activated Partial Thromboplastin Time (aPTT)Time frame: Baseline, Day 4
- Part 2: Change from Baseline in aPTTTime frame: Baseline, Day 1
- Part 1: Change from Baseline in Endogenous Thrombin Potential (ETP) (Thrombin Generation Assay [TGA] Parameter)Time frame: Baseline, Day 4
- Part 1: Change from Baseline in Lag Time (TGA Parameter)Time frame: Baseline, Day 4
- Part 1: Change from Baseline in Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 4
- Part 1: Change from Baseline in Time to Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 4
- Part 2: Change from Baseline in ETP (TGA Parameter)Time frame: Baseline, Day 1
- Part 2: Change from Baseline in Lag Time (TGA Parameter)Time frame: Baseline, Day 1
- Part 2: Change from Baseline in Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 1
- Part 2: Change from Baseline in Time to Peak Thrombin (TGA Parameter)Time frame: Baseline, Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA Health Sciences
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.